Udaya S. Tantry, Kevin P. Bliden, Paul A. Gurbel

Research output: Contribution to journalArticlepeer-review

45 Scopus citations


Oral antiplatelet therapy with P2Y12 receptor blockers (especially clopidogrel) is the current choice of treatment during acute coronary syndromes and percutaneous interventions. To address the various limitations of thienopyridine therapy (including response variability and non-responsiveness) a novel drug, AZD6140, is under clinical development. AZD6140 is an oral and reversible P2Y12 receptor blocker that does not require hepatic conversion to an active metabolite and produces an overall superior ADP-induced platelet inhibition with less response variability than clopidogrel. It has fast onset and offset actions that may be advantageous in patients who may have to undergo immediate surgery.

Original languageEnglish (US)
Pages (from-to)225-229
Number of pages5
JournalExpert Opinion on Investigational Drugs
Issue number2
StatePublished - Feb 2007


  • AZD6140
  • Coronary artery diseases
  • P2Y receptor blocker
  • Platelets
  • Thienopyridines

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'AZD6140'. Together they form a unique fingerprint.

Cite this